Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Merus Logo
Merus Growth Score
53
CB Rank
54255
Heat Score
46
Merus discovers and develops new treatments for cancer using the Multiclonics Platform.
Acquired by
Genmab Logo
Genmab
Founded
obfuscation
PublicPost-IPO Equity Utrecht, Utrecht, The Netherlands251-500 merus.nl
Biotechnology
Health Care
Medical
Oncology
Therapeutics
Overview

Merus
Total Funding
obfuscation
Growth Score
53
Heat Score
46

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score53
-5 pts
in past quarter
Heat Score 46
-7 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Merus

CB Rank
54255
Merus discovers and develops new treatments for cancer using the Multiclonics Platform.
Acquired by
Genmab Logo
Genmab
Founded
obfuscation
PublicPost-IPO Equity Utrecht, Utrecht, The Netherlands251-500 merus.nl
Biotechnology
Health Care
Medical
Oncology
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Merus N.V.
Operating Status Active
Stock Symbol  NASDAQ:MRUS
Company Type For Profit
Founders  Ton Logtenberg
About the Company
Merus is a biotechnology company that discovers and develops new treatments for cancer patients. The company utilizes its proprietary Multiclonics Platform technology to advance its clinical pipeline of medicines. Merus conducts scientific research and clinical trials focused on developing novel treatments.
Phone Number +31 30 253 8800
Contact Email enquiries@merus.nl
Predictions & Insights

Growth Insight

See this Growth Insight
Merus is
Lorem
 to be growing
Top Contributing Factors
Operations Expansion

Products & Services

Petosemtamab (MCLA-158)
A bispecific antibody targeting EGFR and LGR5 for treatment of head and neck squamous cell carcinoma and metastatic colorectal cancer.
BIZENGRI® (zenocutuzumab-zbco)
A bispecific antibody targeting HER2 and HER3 for treatment of NRG1 fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 12
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 12
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Merus Logo
Post-IPO Equity - Merus
—
obfuscation
— Post-IPO Equity

Investors

M&A Details

Merus was acquired by Genmab for
obfuscation
on
obfuscation
. This deal was done in Cash.
Transaction Name 
Merus acquired by Genmab Logo
Merus acquired by Genmab
Acquired by 
Genmab Logo
Genmab
Announced Date 
obfuscation
Price 
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 251-500 Employee Profiles 17 Board Members and Advisors 2 Contacts 211

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 19, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 13, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

3,754
38.83%
 in past month

IT Spend

$1MThis year, Merus is projected to spend $1M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Daily Deals Logo
Daily Deals
81
Team Cadences Logo
Team Cadences
80
Mission Critical Logo
Mission Critical
74

Actively Used Products

34Merus uses 34 technology products and services including HTML5, Office 365, and  Google Doubleclick, according to G2 Stack.

Active Website Tech Count

32Merus is actively using 32 technologies for its website, according to BuiltWith. These include HSTS, Euro, and  Google Tag Manager.

Total IP

109The intellectual property of Merus includes 107 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery. Additionally, Merus has registered 2 trademarks with the most popular class being 'Scientific and technological services', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Merus's headquarters? Merus is located in Utrecht, Utrecht, The Netherlands.Who invested in Merus? Merus has 15 investors including Sofinnova Investments and  EQT Life Sciences.When was the last funding round for Merus? Merus closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Merus's competitors? Alternatives and possible competitors to Merus may include Avenzo Therapeutics, OS Therapies, and  Merck.How much funding has Merus raised to date? Merus has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(9fd75b2 1)
|